undamentalytics Newsletter
Sign in

Organogenesis Holdings Inc. income statement

In fiscal 2025, Organogenesis Holdings Inc. reported revenue of $564m, up 17.0% on the year before, operating income of $44.7m (a 7.9% margin) and net income of $37.0m, or $0.15 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue139199193261338467451433482564457
Cost of revenue4861697687114105106116——
Gross profit91137125185251353346327366——
Research and development69111520314044504557
Selling, general and administrative93134162200204250284270295326299
Operating income−9−5−52−3027722213−145−36
Interest expense68119117222−2−1
Income before tax−15−15−65−3918632010−347−35
Income tax0−7001−3155−41049
Net income−17−8−65−391794165137−84
Diluted EPS−$0.27−$0.14−$0.94−$0.42$0.15$0.70$0.12$0.04−$0.01$0.15−$0.64
Diluted shares (average)63m64m69m93m111m134m132m133m132m130m131m
EBITDA−3−2−48−26317828231260−20

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ORGO vs UFPTMDXG vs ORGOEMBC vs ORGOORGO vs OSUR

More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies

Figures from Organogenesis Holdings Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Organogenesis Holdings Inc.